Comparison of Intravitreal Aflibercept and Ranibizumab for Treatment of Myopic Choroidal Neovascularization: One-Year Results—A Retrospective, Comparative Study
Table 1
The baseline clinical and demographic characteristics of both groups were found statistically comparable in all parameters.
Aflibercept no.: 12
Ranibizumab no.: 18
value
Age (years), mean ± SD
60.0 ± 10.2
57.4 ± 13.1
0.574
Gender, n (%), female
8 (66.6%)
13 (72.2%)
0.677
Lens status, n (%), phakic
5 (41.6%)
9 (50%)
0.434
Baseline BCVA, mean ± SD (logMAR)
1.54 ± 0.76
1.14 ± 0.90
0.172
Baseline CMT (in μm), mean ± SD
384.3 ± 119.1
366.5 ± 102.3
0.697
AL (in mm), mean ± SD
28.4 ± 2.3
29.3 ± 3.1
0.321
Treatment naïve status (%)
75%
78%
0.81
Mean number of treatments in one-year follow-up ± SD
2.9 ± 1.6
2.5 ± 1.6
0.6
The types of mCNVs
58% mixed (type I + II)
61% mixed (type I + II)
0.79
SE mean ± SD in diopters (phakic eyes)
−9.4 ± 1.9
−9.6 ± 1.3
0.512
BCVA, best-corrected visual acuity; CMT, central macular thickness; AL, axial length; mCNV, myopic choroidal neovascular membrane; SE, spherical equivalent.
